Cost-Effectiveness Data Justify ICD Coverage Expansion – Guidant Exec
This article was originally published in The Gray Sheet
Executive Summary
CMS should explicitly consider costs in making its decision whether to expand prophylactic ICD coverage, according to Guidant's Chief Medical Officer Joseph Smith, MD/PhD
You may also be interested in...
CMS Finds Few Allies In Public Comments On Medicare ICD Coverage Policy
CMS' implantable cardioverter defibrillator coverage policy should encourage implantation of value-priced "shock box" ICDs for heart failure patients at risk for sudden cardiac death, according to Biotronik
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.